SOAT1 and diffuse large B-cell lymphoma: STAT3 deregulation is shown to be present in 35-40% of DLBCL cases.[16, 36] The approval of the JAK1/JAK2 inhibitor Ruxolitinib in patients with myeloproliferative neoplasms [37] has increased investigations as to whether inhibiting JAK/STAT signaling will be effective in DLBCL.